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The cholecystokinin (CCK) receptor-2 exerts very im-
portant central and peripheral functions by binding the
neuropeptides cholecystokinin or gastrin. Because this
receptor is a potential therapeutic target, great interest
has been devoted to the identification of efficient antago-
nists. However, interspecies genetic polymorphism that
does not alter cholecystokinin-induced signaling was
shown to markedly affect activity of synthetic ligands. In
this context, precise structural study of the agonist bind-
ing site on the human cholecystokinin receptor-2 is a pre-
requisite to elucidating the molecular basis for its activa-
tion and to optimizing properties of synthetic ligands. In
this study, using site-directedmutagenesis andmolecular
modeling, we delineated the binding site for CCK on the
human cholecystokinin receptor-2 by mutating amino ac-
ids corresponding to that of the rat homolog. By doing so,
we demonstrated that, although resembling that of rat
homolog, the human cholecystokinin receptor-2 binding
site also displays important distinct structural features
that were demonstrated by susceptibility to several point
mutations (F120A, Y189A, H207A). Furthermore, docking
of CCK in the human and rat cholecystokinin receptor-2,
followed by dynamic simulations, allowed us to propose a
plausible structural explanation of the experimentally ob-
served difference between rat and human cholecystoki-
nin-2 receptors.
Cholecystokinin (CCK)1 and gastrin are two regulatory pep-
tides having high affinity for CCK receptors. Both peptides
share an identical carboxyl-terminal pentapeptide sequence
but differ in their selectivity for the two CCK receptor sub-
types, the CCK1 (CCK1R) and the CCK2 (CCK2R) receptors,
on the basis of tyrosine sulfation at the seventh position (CCK)
or at the sixth position (gastrin) from the carboxyl terminus.
Although both receptors recognize sulfated CCK with compa-
rable high affinity, the CCK2R has high affinity for both sul-
fated and non-sulfated gastrin (1, 2). CCK1R and CCK2R are
seven-transmembrane spanning receptors that belong to the
superfamily of G protein-coupled receptors and have 50%
homology (3–5). CCK1Rs are mainly found in the peripheral
organs, where they regulate pancreatic secretion and gallblad-
der and gastrointestinal motility, but are also found in some
areas of the central nervous system, where they regulate sati-
ety and analgesia. CCK2Rs are predominantly present
throughout the central nervous system, where they regulate
anxiety/panic attacks and dopamine release, implicated in the
pathogenesis of dopaminergic related movement and behav-
ioral disorders in humans. In the gut, CCK2Rs regulate acid
and histamine secretions, gastrointestinal motility, as well as
growth in the gastric mucosa (1, 2). The important physiologi-
cal functions mediated by CCK receptors, and therefore their
possible implication in associated disorders, have generated
considerable interest in the identification of ligands that selec-
tively activate or block CCK1R and CCK2R (6). To date, a large
panel of such molecules has been designed covering a wide
range of functional activities, such as full, partial, and inverse
agonists, as well as antagonists (6). Pharmacological charac-
terization of selective synthetic CCK2R ligands among differ-
ent species pointed out an interspecies genetic polymorphism
that does not alter endogenous hormone-induced signaling but
markedly affects both the affinity and activity of synthetic
ligands (7). This is the case for L-365,260 and L-364,718, two
reference non-peptidic CCK2R antagonists that present rever-
sal in the affinity rank order on canine or human recombinant
CCK2R despite a 93% identity in their protein sequence (8).
Furthermore, efficacy of PD-135,158, a CCK2R partial agonist,
is 60% of CCK-induced maximal production of inositol phos-
phates on mouse CCK2R but only 20% on human CCK2R,
despite 90% identity (9). These interspecies differences toward
synthetic ligands were shown to be caused by sequence varia-
tions within the binding site of the CCK2R (7). Such data
pointed out the high importance of in vivo and in vitro tests
with human protein targets.
The aims of the present study, using site-directed mutagen-
esis and molecular modeling, were to delineate the binding site
for CCK on the human CCK2R and to investigate whether
insensitivity of endogenous ligands to interspecies polymor-
phism between rat and human CCK2R can be explained by
differences in their positioning into the CCK2R binding site or
whether they are related to distinct susceptibilities to muta-
tions. For that purpose, we took advantage of our previous
data, which demonstrated an interaction between His207 of rat
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CCK2R and Asp8 of CCK, between the Tyr189 and Asn358 res-
idues of rat CCK2R and the carboxyl-terminal amide of CCK
(10), as well as the contribution of Arg57 and Phe120 residues in
CCK high affinity binding (11, 12). These key amino acids of
the CCK2R binding site were mutated in the human CCK2R,
and the mutant receptors were characterized for CCK affinity,
as well as efficacy and potency, to stimulate inositol phosphates
accumulation. By doing so, we demonstrated that, although
resembling that of rat CCK2R, the human CCK2R binding site
also displays important distinct structural features that are
confirmed by susceptibility to point mutations and docking,
followed by dynamic simulations.
EXPERIMENTAL PROCEDURES
Materials—Sulfated [Thr28,Nle31]CCK25–33 (H-Arg-Asp-Tyr(SO3H)-
Thr-Gly-Trp-Nle-Asp-Phe-NH2, CCK9S), was synthesized as described
previously (13). 125I-Sodium (2000 Ci/mmol) was from Amersham Bio-
sciences. Sulfated [Thr28,Nle31]CCK25–33 was conjugated with Bolton-
Hunter reagent, purified, and radioiodinated as described previously
(14) and is referred to as [125I]CCK9S.
Site-directed Mutagenesis and Transfection of COS-7 cells—All mu-
tant receptor cDNAs were constructed by oligonucleotide-directed mu-
tagenesis (QuikChangeTM site-directed mutagenesis kit, Stratagene)
using the human CCK2R cDNAs cloned into pRFENeo vector as a
template. The presence of the desired and the absence of undesired
mutations were confirmed by automated sequencing of the complete
CCK2R coding sequence (Applied Biosystems).
COS-7 cells (1.5  106) were plated onto 10-cm culture dishes and
grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 5%
fetal calf serum in a 5% CO2 atmosphere at 37 °C. After overnight
incubation, the cells were transfected with 0.5 g/plate of pRFENeo
vectors containing the cDNA for the wild-type or mutated CCK2 recep-
tors, using a modified DEAE-dextran method as described previously
(10). The cells were transferred to 24-well plates at a density of 20,000–
150,000 cells/well 24 h after transfection, depending on the transfected
mutant and the experiment to be performed.
Binding Experiments—Approximately 24 h after the transfer of the
transfected cells to 24-well plates, the cells were washed with phos-
phate-buffered saline, pH 7.4, containing 0.1% bovine serum albumin
and then incubated for 60 min at 37 °C in 0.3 ml of DMEM containing
0.1% bovine serum albumin, with either 50 pM (wild-type CCK2R,
R356K), 100 pM (R57A, F120A, Y189F), 250 pM (H207A, N358A, Y189A,
R356A, R356H) or 500 pM (R356D) [125I]CCK9S in the presence or in
the absence of unlabeled CCK9S. The cells were washed twice with cold
phosphate-buffered saline, pH 7.4, containing 2% bovine serum albu-
min, and cell-associated radioligand was collected by cell lysis with
NaOH 0.1 N. The radioactivity was directly counted in a  counter
(Auto-, Packard, Downers Grove, IL). Receptor density and Kd were
calculated from homologous [125I]CCK9S/CCK9S competition binding
experiments using Ligand software (Kell, Cambridge, UK). Ki values
were calculated using the non-linear curve fitting software GraphPad
Prism (San Diego, CA).
Inositol Phosphate Assay—Approximately 24 h after the transfer to
24-well plates and following overnight incubation in DMEM containing
2 Ci/ml myo-2-[3H]inositol (Amersham Biosciences), the transfected
cells were washed with DMEM and then incubated for 30 min in 1
ml/well DMEM containing 20 mM LiCl at 37 °C. The cells were washed
with inositol phosphate buffer, pH 7.45, phosphate-buffered saline con-
taining 135 mMNaCl, 20 mMHEPES, 2 mM CaCl2, 1.2 mMMgSO4, 1 mM
EGTA,10 mM LiCl, 11.1 mM glucose, and 0.5% bovine serum albumin.
The cells were then incubated for 60 min at 37 °C in 0.3 ml of inositol
phosphate buffer with or without increasing CCK9S concentration. The
reaction was stopped by adding 1 ml of methanol/HCl to each well, and
the content was transferred to a column (Dowex AG 1-X8, formate form,
Bio-Rad, Hercules, CA) for the determination of inositol phosphates.
The columns were washed twice with 3 ml of distilled water and twice
with 2 ml of 5 mM sodium tetraborate/60 mM sodium formate. The
content of each column was eluted by the addition of 2 ml of 1 M
ammonium formate/100 mM formic acid. Radioactivity of 1 ml of the
eluted fraction was evaluated using a liquid scintillation counter (Pack-
ard Instrument Co.). EC50 values were calculated from dose effect
curves by non-linear regression curve fitting using GraphPad Prism
software (San Diego, CA).
Molecular Modeling of Human CCK2RCCK Complex and Dynamic
Simulations—The human CCK2R model was built by homology mod-
eling from the rat CCK2RCCK complex model described by Gales
et al. (11) using Insight II modules (Homology, Discover 3, Biopolymer,
Accelrys, San Diego, CA). Alignment of the human CCK2R sequence on
the rat CCK2R sequence was performed using the alignment procedure
followed by manual refinement so that motifs common to all G protein-
coupled receptors and conserved amino acids between the two se-
quences precisely matched. The coordinates of the human CCK2R were
then assigned to those of the rat CCK2R three-dimensional model,
based on this alignment. The resulting model was finally submitted to
energy minimization by the steepest descent (until convergence to 2
kcal/mol/Å) and conjugated gradient (until convergence to 0.01 kcal/
mol/Å) to remove steric clashes. During minimization, C- trace was
tethered using a quadratic potential. This was performed using the
Discover 3 module with the consistent force field. The non-bond cutoff
method and the dielectric constant were set up to cell multipole and
were distance-dependent, respectively (e  r). The minimized model of
human CCK2 receptor was used to perform manual docking of CCK.
The conformation of CCK was taken from the optimized complex of rat
CCK2RCCK (11), and docking was performed taking into account the
position of CCK in that receptor. The obtained human CCK2RCCK
complex was minimized again according to the previously described
minimization protocol, with no C- restraints, and was further sub-
jected to molecular dynamics in a two-step procedure. In the first step,
the complex was heated from 10 K up to 300 K during 5000 fs, and in
the second step, it was kept at 300 K until equilibration. The tethering
force on the C- trace was kept in heating and was successively de-
creased by reducing the force constant value of the quadratic potential
from 100 to 80, 50, 30, 10, and 0 every 1000 ps in the second step. The
integration time step was set up to 1 fs, and the calculations were
performed at constant volume and temperature. A snapshot of the system
was saved every 100 fs. Once the system was equilibrated, the coordi-
nates of 20 snapshots were averaged and submitted again to the pre-
viously mentioned minimization protocol, with no C- restraints.
RESULTS
Effects of R57A, F120A, H207A, Y189F, Y189A, and N353A
Mutations in the Human CCK2R on CCK Affinity and Potency—
Human R57A, F120A, H207A, Y189A, Y189F, and N353A mu-
tants were constructed and transiently expressed in COS-7
cells. Scatchard analysis of [I125]CCK9S binding to the wild-
type human CCK2R indicated that CCK9S binds to high affin-
ity sites with Ki values of 0.75  0.03 nM (Bmax 3.2  0.3 pmol/
106 cells) (Tables I and II). Mutation of Arg57 and Phe120 in
alanine or mutation of Tyr189 in phenylalanine slightly re-
duced, between 4- and 6-fold, CCK9S affinity with Ki values of
3.4  0.4 nM (Bmax 0.85  0.09 pmol/10
6 cells), 3.1  0.4 nM
(Bmax 0.79  0.08 pmol/10
6 cells), and 4.3  0.4 nM (Bmax
1.1  0.2 pmol/106 cells), respectively (Tables I and II). Y189A,
H207A, and N353A mutants displayed between 25- and 73-fold
decreased affinity for CCK9S with respective Ki values of
55  8 nM (Bmax 2.7  0.5 pmol/10
6 cells), 19  2 nM (Bmax
1.1  0.1 pmol/106 cells), and 20  2 nM (Bmax 0.8  0.1 pmol/
106 cells) (Tables I and II). In agreement with binding data, the
potency of CCK9S to stimulate inositol phosphate accumula-
tion was reduced for all mutants (EC50) and directly correlated
with the loss of affinity for CCK9. The mutants displayed
CCK9S efficacy (Emax, Table I) comparable with that of wild-
type CCK2R, except for the Y189A mutant, which presented a
44% decrease of CCK9Smaximal effect despite similar receptor
density (Table I). Comparison of these results with those from
our previous studies performed in exactly the same experimen-
tal conditions on rat CCK2R mutants reveals that, except for
N353A mutation (the human corresponding mutant of rat
N358A), all of the mutations carried out on the human CCK2R
less markedly affected CCK affinity and activity, supporting
the view that the corresponding residues are differentially
involved in the binding sites of the two CCK2Rs (Table II, Fwt).
Effects of R356A, R356H, R356K, and R356D Mutations in
Human CCK2R on CCK Affinity and Potency—Our previous
studies (15) on the binding site of the human CCK1R demon-
strates that Arg336, located at the top of TM 6, highly contrib-
utes to the binding of CCK. Because the homologous amino acid
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in the human CCK2R is Arg356, we determined whether this
residue could also be involved in the binding site of the human
CCK2R. For this purpose, R356A, R356H, R356K, and R356D
mutants were constructed and analyzed. These mutants were
designed to remove partially or completely the positive charges
of this arginine (R356A, R356H, and R356K mutants) or to
introduce a negative charge at that position (R356D mutant).
Mutation of Arg356 in lysine did not modify CCK9S affinity
(Ki  0.50  0.05 nM, Bmax 3.9  0.4 pmol/10
6 cells) nor the
potency and efficacy of CCK9S to stimulate inositol phosphate
accumulation (EC50  0.54  0.06 nM). Replacement of Arg
356
by a histidine or an alanine reduced 10- and 76-fold, respec-
tively, CCK9S affinity, whereas R356D displayed a 932-fold
lower affinity relative to the high affinity component of the
wild-type human CCK2R (Table I and Fig. 1). In agreement
with binding data, R356H, R356A, and R356D mutants dis-
played reduced CCK9S potencies to stimulate inositol phos-
phate accumulation but unchanged efficacy (Table I and
Fig. 1). These results indicate that positive charges of the
amino acid side chain at position 356 of the CCK2R are impor-
tant for high affinity binding of CCK.
Structural Study of Human CCK2R Binding Site Using
Docking and Dynamic Simulations—Results from the current
site-directed mutagenesis study support the view that homol-
ogous residues in the human CCK2R binding sites are differ-
entially involved in the binding site of CCK compared with rat
CCK2R, which we previously characterized. Because human
and rat CCK2R present non-conserved amino acids in extra-
cellular domains and transmembrane helices (Fig. 2), in a first
attempt to explain distinct involvement of His207, we ex-
changed the neighboring amino acid, namely Val206, for the
corresponding amino acid of the rat sequence, Met. However,
the resulting CCK2R mutant (V206MH207A) did not display
an altered pharmacological profile, as compared with the hu-
man H207A mutant (not shown). We also considered the pos-
sibility that His207, which can exist in different tautomeric
forms, could be differently protonated in human and rat
CCK2R. However, pK calculations using the Poisson-Boltz-
mann equation and the generalized Born approach (embodied
in the website chekhov.cs.vt.edu/completion/index.php) yielded
similar values (pK, for rat 3.3 and 4.2, and for human 3.5 and
4.6) thus ruling out this hypothesis. This led us to hypothesize
that non-conserved amino acids, including those in transmem-
brane helices, likely act collectively to position differently CCK
in the binding site of the human CCK2R relative to the rat
CCK2R. We therefore performed in silico experiments by build-
ing a three-dimensional structure of the human CCK2RCCK
complex based on the coordinates of the rat CCK2RCCK com-
plex that we previously experimentally validated (11). There-
after, we applied molecular dynamics to assess whether varia-
tions in the CCK2R sequence could result in a distinct location
of CCK that could explain pharmacological results. A simplified
view of the obtained human CCK2RCCK complex is presented
in Fig. 3, A and C. The docking, followed by dynamic simula-
TABLE I
Effects of mutations of amino acids of the human CCK2R on binding affinity and biological activity of CCK9S
Binding properties and biological potency of mutated CCK2R were determined as described under “Experimental Procedures.” Mutation factors
(Fwt) were calculated as Kd (mutated CCK2R)/Kd (WT-CCK2R) or EC50 (mutated CCK2R/EC50 (WT-CCK2R). Emax values are expressed in percent
of wild-type receptor maximal inositol accumulation in response to 1 M CCK9S. Results represent the means  S.E. of at least three independent
experiments performed in duplicate on separately transfected COS-7 cells.
Binding Inositol phosphate production
High affinity Low affinity Bmax
EC50 FWT° Emax
Kd1 F1WT° Kd2 F2WT° High affinity Low affinity
nM nM pmol/106 cells nM
WT 0.37  0.02 1 2.8  0.3 1 0.89  0.05 2.3  0.2 0.34  0.05 1 100
R57A 1.3  0.3a 4 22  3a 8 0.19  0.04 0.66  0.05 2.2  0.4a 6 100  2
F120A 1.2  0.2a 3 17  4a 6 0.14  0.03 0.65  0.05 1.6  0.2a 5 99  2
Y189F 3.2  0.5a 9 21  4a 8 0.28  0.05 0.82  0.18 3.7  0.4a 11 97  3
Y189A 50  5a 136 436  24a 156 0.45  0.05 2.2  0.5 37  6a 109 56  2a
H207A 8.3  1.4a 27 51  5a 18 0.31  0.05 0.78  0.13 12  2a 35 97  2
N353A 12  1a 32 114  5a 41 0.17  0.06 0.62  0.04 11  1a 32 99  2
R356K 0.38  0.02 1 3.2  0.4 1 1.1  0.1 2.8  0.3 0.54  0.06 1.6 100  2
R356H 3.8  0.3a 10 51  10a 18 0.21  0.05 0.71  0.13 4.1  0.5a 12 100  3
R356A 28  2a 76 0.49  0.04 22  4a 65 100  3
R356D 345  35a 932 1.1  0.1 76  6a 224 100  2
a p  0.05 evaluated by Mann-Whitney test as compared to wild-type receptor value.
TABLE II
Differential effects of mutations of human or rat CCK2R on CCK9S affinity and potency
Binding properties and biological potency of mutated CCK2R were determined as described under “Experimental Procedures.” Mutation factors
(Fwt) were calculated as Kd (mutated CCK2R)/Kd (WT-CCK2R) or EC50 (mutated CCK2R/EC50 (WT-CCK2R)). Emax values are expressed in percent
of wild-type receptor maximal inositol accumulation in response to 1 M CCK9S. Results represent the means S. E. of at least three independent
experiments performed in duplicate on separately transfected COS-7 cells.
Human CCK2R Rat CCK2R
Binding IP accumulation Binding IP accumulation Ref.
Ki FWT° EC50 FWT° FWT° FWT°
nM nM
CCK2 0.75  0.03 1 0.34  0.05 1 1 1
R57A 3.4  0.4a 5 2.2  0.4a 6 21 12
F120A 3.1  0.4 4 1.6  0.2a 5 440 12
Y189F 4.3  0.4a 6 3.7  0.4a 11 30 61 11
Y189A 55  8a 73 37  6a 109a 842 NAb
H207A 19  2a 25 12  2a 35 456 302 10
N353A 20  2a 27 11  1a 32 19 30 11
a p  0.05 evaluated by Mann-Whitney test as compared to wild-type receptor value.
b NA, no accumulation of inositol phosphates.
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tions, revealed that Arg1 and Asp2 of CCK form internal ionic
bonds; sulfated Tyr3 of CCK is in ionic interaction with Arg57
and makes a hydrogen bond with Tyr61; Thr4 forms a hydrogen
bond with Arg356; Trp6 forms both a hydrogen bond with His376
and aryl sulfur interactions with Met67 and Cys107 and hydro-
phobic interactions with Phe120 and Phe110; Nle7 lies in an
hydrophobic pocket composed of Pro371, Trp355, and Leu367; the
carboxyl group of Asp8 interacts with Arg356 and Ser131; the
phenyl group of Phe9 is sited in an aromatic pocket made of
Tyr189, Tyr192, Tyr350, Trp346, Phe342, and Phe227; and the
carbonyl group of CCK amide forms hydrogen bound with the
hydroxyl group of Tyr189, whereas NH2 of the CCK amide
interacts with Asn353 and Thr193 (Fig. 3A). According to these
results, the binding site of the human CCK2R resembles that of
the rat CCK2R. However, and importantly, CCK drifts deeper
in the human CCK2R, representing a difference of 1.5 Å, and
the C-terminal part of CCK between Trp6 and Phe9 displays a
deviation of the backbone of 2.5 Å, as compared with rat
CCK2RCCK complex, which was subjected to the same proce-
dure of dynamic simulations (see Fig. 3C for comparison). In
addition, the phenyl group of Phe9 has an affected orientation,
as compared with the rat complex, where it approximated
Tyr189. In the human complex, Phe9 seems more inserted in a
cavity composed of Tyr189, Tyr192, Tyr350, Trp346, Phe342, and
Phe227 (Fig. 3, A and B). Moreover, Asp8 forms stable ionic
interactions mostly with Arg356 but less with His, which dom-
inated in the rat complex.
DISCUSSION
Despite the high degree of homology between species ho-
mologs of the CCK2 receptor (ranging from 84 to 93%), phar-
macological studies have demonstrated that interspecies poly-
morphism can significantly alter both the affinity and activity
of synthetic ligands (7). Other examples describing polymor-
phism-induced alteration can be found in the literature for
neurokinin, serotonin, and VIP receptors (16–18), but in those
cases, both endogenous and synthetic ligands are affected.
However, in the case of CCK2R, comparison of CCK or gastrin
affinity and activity in cells that express canine, murine, or
human recombinant CCK2R revealed similar profiles. It is
suggested that the apparent insensitivity of endogenous ligand
to receptor polymorphism might be explained by evolutionary
selection, which resulted in the elimination of receptor variants
that compromised endogenous ligand function (7). In this con-
text, the aim of the present study was to delineate the binding
site for CCK on the human CCK2R and to investigate whether
FIG. 1. Importance of R356 of CCK2R for binding of CCK (A) and production of inositol phosphates (B). A, CCK9S competition curves
of specific [125I]CCK9S binding. B, dose-effected curves of CCK9S. Both induced inositol phosphate production in COS cells expressing wild-type
CCK2R (close circles), R356K (open circles), R356H (open squares), R356A (open triangles), or R356D (open diamonds) mutants. Results represent
the means  S.E. of three independent experiments in duplicate performed on separately transfected COS-7 cells.
FIG. 2. Serpentine representation of the human CCK2R. On this representation of the human CCK2R, amino acids Arg57, Phe120, His207,
Tyr189, Asn353, and Arg356, which are corresponding amino acids of the rat CCK2R binding site of CCK, are indicated. Moreover, non-conserved
amino acids between human and rat CCK2R are shown and numbered. , potential N-glycosylation sites.
Human Cholecystokinin Receptor-2 Binding Site 22201










insensitivity of endogenous ligands to interspecies polymor-
phism between rat and human CCK2R can be explained by
differences in their location into the CCK2R binding site or
whether there are related to distinct susceptibilities to
mutations.
Using site-directed mutagenesis and pharmacological stud-
ies, we found that some mutations were less unfavorable when
performed on the human CCK2R than on the rat receptor. The
magnitude of the differences between rat and human mutants
varied depending on the amino acid studied. Mutation of Arg57
(located at the top of the first transmembrane domain) in
alanine reduced 5-fold the CCK affinity in the human receptor
versus 21-fold in rat receptor (12). Similarly, Kopin et al. (19)
have shown that the human R57Q mutant displayed a 6-fold
decreased affinity for CCK, confirming the slight contribution
of Arg57 in the human CCK2R for high affinity binding of CCK.
Moreover, photoaffinity labeling experiments, using a CCK
ligand having its photosensitive moiety attached to its N ter-
minus, identified amino acids at the top of helix I, which agrees
with current results supporting that the sulfate of CCK slightly
interacts with Arg57 (20). Surprisingly, Phe120, located in the
first extracellular loop and which is essential for the high
affinity binding of CCK to the rat CCK2R, does not appear to be
as essential in human CCK2R. Indeed, mutation F120A in the
rat receptor resulted in complete loss of radioligand binding
(12), whereas in the current study, the human F120A mutant
FIG. 3. Modeled structure of the CCK2R binding site for CCK. a, the human CCK2R binding site. This side view shows the three-
dimensional refined model of the active high affinity human CCK2R binding site. The model was built by homology, as described under
“Experimental Procedures,” using a previously validated rat CCK2R model as a template. Thereafter, the three-dimensional model was refined
according to the method detailed under “Experimental Procedures.” The program package from Accelerys (San Diego, CA) was used. For clarity,
the view shows only identified amino acid side chains of the CCK2R (green) in interaction with CCK (orange). b, focused side view of the binding
site of the C-terminal end of CCK in the human CCK2R. This view shows how the C-terminal Phe of CCK (orange) is inserted in a cavity formed
of aromatic residues (green), the relative position of which is maintained by quadrupole-quadrupole interactions between Met234 and Phe342. c and
d, comparison between human and rat CCK2R binding sites for CCK. Rat and human CCK2R protein traces were superimposed. The CCK2Rs are
shown from two different angles of view to better display differences at the top of binding sites (c) and within the deepest part of the binding cavity
(d). In human CCK2R (dark green residues and numbering), carbon atoms of CCK are shown in orange. In the rat CCK2R (pink residues and
numbering), carbon atoms of CCK are shown in cyan.
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only displayed a 4-fold lower affinity as compared with wild-
type CCK2R. Similar results were obtained with the H207A
mutant. Our previous results with the rat receptor clearly
demonstrated a direct interaction between His207, located in
the second extracellular loop, and penultimate aspartic acid of
CCK (10). Here, the contribution of His207 in the human
CCK2R binding pocket is quantitatively different. Indeed, the
human H207A mutant displayed a 25-fold lower CCK affinity
versus 456-fold in the rat (10). Taken together, all of the results
thus suggest that the contribution of extracellular residues of
human CCK2R is less important than in the rat CCK2R, and
most of the residues involved in high affinity binding of CCK
are probably located in transmembrane domains.
We next evaluated, in human CCK2R, the contribution of
Tyr189 and Asn353, the corresponding amino acids of rat Tyr189
and Asn358 known to make direct interaction with the C-ter-
minal amide of CCK (11). Human N353A and rat N358A mu-
tants displayed a similar pharmacological profile with respect
to CCK affinity and activity, suggesting that, as in the rat
receptor, Asn353 located at the top of the sixth transmembrane
domain directly interacts with the C-terminal amide of CCK. In
contrast, the contribution of Tyr189 is different in human and
rat receptors. Mutation of Tyr189, located at the top of the
fourth transmembrane domain, in phenylalanine or alanine
reduced by 6- and 73-fold CCK affinity in the human receptor
versus 30- and 842-fold in the rat receptor, respectively. In
addition, the human Y189A mutant displayed a reduced CCK
potency (109-fold) and efficacy (44%) to stimulate inositol phos-
phate accumulation, whereas the rat Y189A mutant was found
to be unable to produce inositol phosphates (11). Even if human
Y189A mutant is less affected than rat Y189A mutant, our
results are compatible with an involvement of the Tyr189 aro-
matic ring in CCK2R activation (reduced potency and efficacy).
We also evaluated the contribution of Arg356, located at the top
of the sixth transmembrane domain. Mutation of Arg356 in
lysine did not modify CCK affinity, whereas its mutation in
histidine or alanine reduced by 9- and 76-fold CCK affinity,
respectively, suggesting that the presence of positive charges is
important for high affinity binding of CCK. The R356D mutant
displays an even lower affinity for CCK (413-fold reduction)
that likely reflects electrostatic repulsion between CCK and
R356D mutant. Interestingly, we previously demonstrated
that, in human CCK1R, the corresponding amino acid (Arg336)
interacts with the penultimate aspartic acid of CCK (15).
Detailed analysis of the human- and rat-modeled
CCK2RCCK complexes allows us to propose structure-based
explanations for the different mutational data obtained in hu-
man and rat CCK2R. According to dynamic simulations, CCK
drifts deeper in the human CCK2R than in the rat CCK2R,
leading the peptidic backbone corresponding to the C-terminal
region of CCK (which is the most important for recognition by
the CCK2R) to site 2.5 Å deeper in the receptor binding
pocket. This can influence the contributions of several extra-
cellular key residues to the binding of CCK, especially because
these belong to flexible extracellular loops 1 and 2. For exam-
ple, Phe120 is less important for CCK recognition in human
CCK2R than in rat CCK2R. This is likely the result of an
increase of the collective contribution of other residues, such as
His376, Met67, Cys107, and Phe110, to the binding site of the
human CCK2R. This view fully agrees with previous mutagen-
esis data showing that exchange of His376 for a leucine de-
creased the affinity of CCK8 for the human CCK2R by 30-fold,
whereas mutation of the corresponding amino acid in the rat
CCK2R did not affect CCK8 recognition (19, 21).
Thereafter, we demonstrated that different contributions of
His207 in human versus rat CCK2R were likely not due to
different protonated states. Alternatively, the deepest location
of the CCK molecule within the binding site of the human
CCK2R compared with rat CCK2R could favor interactions of
the Asp side chain of CCK with Arg356, to the detriment of
His207. Furthermore, there is a Val at position 130 in human
CCK2 and an Ile in the rat receptor. Due to the possible
hindrance of amino acid side chains, one can suggest that the
Val residue favors interaction with Arg356, whereas Ile can
favor interaction with His207.
Concerning the lower contribution of Tyr189 in the human
CCK2R binding site (as compared with rat CCK2R), in both
cases, two types of interactions are seen in the modeled struc-
ture: a hydrogen bond with the carbonyl group of Phe9 of CCK
and - electronic interactions between the two rings. How-
ever, the relative positions of the two aromatic rings (Tyr189
and Phe9 of CCK) are sufficiently different in the human versus
the rat complexes to explain the mutagenesis results. In fact,
according to dynamic simulation experiments, the relative po-
sition of Tyr189 and Phe9 of CCK, and therefore the location of
CCK, within the binding pocket appears to be at least partially
governed by the presence of Met234 (TM V) in the human
CCK2R instead of an isoleucine in the rat receptor, and con-
versely, the presence of Met194 (TM IV) in the rat CCK2R
instead of a valine in human receptor. In the modeled human
CCK2R, Met234 forms a sulfur- interaction with Phe342, which
in turn can influence the aromatic network comprising resi-
dues Phe342, Trp346, Phe227, and Tyr350 (Fig. 3, B and C). In the
rat CCK2R, it is Met194 that can influence this aromatic net-
work but in an opposite way. Interactions between methionine
and aromatic residues, such as Phe and Tyr, are recognized to
play an important role in the three-dimensional structure and
function of many proteins. For instance, in the CCK1R, a Met
residue located in the second extracellular loop was demon-
strated to play a key role for correct positioning of Tyr(SO3H) of
CCK toward its interacting partner, Arg197 (22, 23). In this
receptor, another methionine in helix III was demonstrated to
govern receptor coupling to G protein by influencing the hydro-
phobic pocket, which positions Phe of CCK relative to an aro-
matic residue of helix VI (24). The physicochemical basis of
interactions between a sulfur atom and aromatic ring has been
investigated and was claimed to explain why, in the protein
data base, 50% of the sulfur atoms are contacting aromatic
rings (25).
Analysis of data from studies of other groups reinforces our
current findings, showing that conserved residues in the
CCK2R among different species contribute differently in CCK
high affinity and CCK2R activation. First, although residue
Trp346 of the human CCK2R belongs to the aromatic network
(Fig. 3, A and B), its exchange for an alanine did not affect
pharmacological properties of the receptor (26). In contrast, the
corresponding mutation in the rat receptor caused a 34% de-
crease of inositol phosphate accumulation and a 10-fold de-
crease of both CCK affinity and potency (27). This is consistent
with dynamic simulation data predicting that the C-terminal
phenylalanine of CCK makes stacking ring-ring interactions
with Tyr189 and Trp351 (corresponding to human Trp346) lo-
cated in the sixth transmembrane domain. This is also in line
with the key role of Tyr189 in the activation of the rat CCK2R
that we documented using site-directed mutagenesis (11). Sec-
ond, the key role of Phe342 (TM VI) in the aromatic network and
the fact that in the human CCK2R this residue interacts with
Met234 (TM V) must be compared with findings that the corre-
sponding residue in the rat sequence (Phe347) is crucial for
activation of phospholipase-C by the CCK2R (27, 28). Third,
the works of Kopin and colleagues (19, 26) points out the
importance of Tyr61 (junction between TM I and N-terminal
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region), Met186 (TM IV), and Thr193 for CCK binding to the
human CCK2R. Their data are fully compatible with the re-
fined human CCK2RCCK complex, which shows hydrogen
bonds involving Tyr61 and Tyr of CCK as well as Thr193 and the
amide of CCK (Fig. 3A). On the other hand, the role of Met186
is likely indirect and linked to the aromatic network within the
binding pocket. Using NMR nuclear Overhauser enhancement
transfer, Mierke and co-worker (29) proposed interactions be-
tween Trp and Met of CCK with Pro371 and Phe374 (TM VII). In
our modeled structure, Nle, which mimics Met of CCK, approx-
imates Pro371. It is interesting to note that there is a good
overlapping between the binding site for the C-terminal of CCK
and the suggested binding site of non-peptide ligands, as indi-
cated by the delete/rescue approach in which deleterious mu-
tations within the receptor were rescued by subsequent modi-
fication of the ligand (30).
To conclude, delineation of the CCK binding site of the hu-
man CCK2R, using site-directed mutagenesis and docking fol-
lowed by dynamic simulations, allowed us to demonstrate that,
although roughly resembling that of the rat CCK2R, this bind-
ing site also displays important distinct structural features
that are confirmed by susceptibility to point mutations. These
new important data, together with our experience with the
CCK1R (31), will be used to understand how some of the so-
called non-peptide antagonists present partial agonist activi-
ties (7). This goal is of timely importance due to the fact that
CCK2R is a biological target of therapeutic interest (6).
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